Jazz Pharmaceuticals(US:JAZZ)2026-02-24 21:10Patient and Product Information - Jazz Pharmaceuticals reported approximately 16,175 patients taking Xywav by the end of 2025, including about 10,950 with narcolepsy and 5,225 with idiopathic hypersomnia (IH) [445]. - Xywav has demonstrated a 92% reduction in sodium content compared to Xyrem, making it a safer option for patients with narcolepsy and IH [442]. - The company achieved benefit coverage for Xywav in both narcolepsy and IH for approximately 90% of commercial lives in the U.S. [444]. - Epidiolex, acquired in May 2021, is approved for treating seizures associated with LGS, DS, and TSC, and is now launched and reimbursed in over 40 countries [446]. - Ziihera received accelerated approval from the FDA in November 2024 for treating adults with previously treated, unresectable or metastatic HER2-positive BTC [448]. - The FDA recognized seven years of orphan drug exclusivity (ODE) for Xywav in narcolepsy through January 2028 [442]. - The company focuses on rare diseases, which often have high unmet needs and small patient populations, allowing for efficient commercialization [435]. - Jazz Pharmaceuticals aims to leverage its scalable operating model to effectively reach patients globally [435]. Research and Development - The company continues to invest in R&D programs that align with its rare disease strategy [436]. - JZP898, a differentiated immuno-oncology molecule, entered Phase 1 trials after a $15 million upfront payment to Werewolf, with potential milestone payments up to $1.26 billion [463]. - JZP053, a preclinical epilepsy treatment, was licensed from Saniona for $42.5 million upfront, with potential milestone payments up to $800 million [465]. - The company initiated a Phase 1b trial for Epidiolex to evaluate its effectiveness in reducing focal seizures, with ongoing trials for multiple product candidates including zanidatamab and Vyxeos [466]. - Zanidatamab's Phase 3 HERIZON-GEA-01 trial showed statistically significant progression-free survival and overall survival benefits in HER2-positive locally advanced or metastatic GEA [470]. - The company has ongoing trials for multiple oncology products, including Rylaze, Zepzelca, Ziihera, Modeyso, Vyxeos, and Defitelio, which are critical for its growth strategy [476]. - The company’s growth strategy includes continued investment in R&D activities, with potential risks if clinical development does not succeed or regulatory approvals are delayed [477]. Financial Performance - Product sales for 2025 reached $4,021,849, a 5% increase from 2024's $3,821,164 [485]. - Xywav product sales increased by 12% in 2025, driven by a 14% increase in sales volumes, with 10,950 patients using it for narcolepsy and 5,225 for idiopathic hypersomnia (IH) by the end of 2025 [490]. - Xyrem product sales decreased by 38% in 2025, primarily due to a 33% drop in sales volumes attributed to competition from high-sodium oxybate [488]. - Epidiolex/Epidyolex product sales increased by 9% in 2025, mainly due to a 7% increase in sales volumes driven by higher demand [490]. - Total revenues for 2025 were $4,267,586, reflecting a 5% increase from $4,068,950 in 2024 [488]. - Selling, general and administrative expenses rose by 31% in 2025 to $1,809,271, compared to $1,385,294 in 2024 [485]. - Research and development expenses decreased by 11% in 2025 to $782,736, down from $884,000 in 2024 [485]. - Interest expense decreased by 18% in 2025 to $195,051, compared to $238,097 in 2024 [485]. - The company anticipates potential adverse effects on margins due to increased tariffs on imported pharmaceutical products starting as early as fiscal 2026 [483]. - The IRA mandates price negotiations for certain high Medicare spend drugs starting in 2026, which could limit commercial opportunities and negatively impact revenues [479]. Product Sales and Market Dynamics - Defitelio/defibrotide product sales decreased by 8% in 2025 compared to 2024, while Vyxeos product sales decreased by 10% in the same period, both primarily due to decreased sales volumes [493][496]. - Modeyso product sales were $48.0 million in 2025 following its launch in August 2025, and Ziihera product sales were $24.8 million in 2025 after its launch in December 2024 [493]. - Total revenues in 2026 are expected to increase compared to 2025, driven by growth in rare oncology and epilepsy products, offset by a reduction in oxybate revenues [495]. - Cost of product sales increased in 2025 compared to 2024, with a gross margin of 87.5% in 2025, down from 88.3% in 2024 [496]. - Selling, general and administrative expenses increased by $233.5 million due to Xyrem antitrust litigation settlements in 2025 [498]. - R&D expenses decreased by $101.3 million in 2025 compared to 2024, totaling $782.7 million, primarily due to lower costs related to clinical trials [501]. - The company faces competition from generic versions of high-sodium oxybate, with Amneal and Hikma launching their AG products, which could negatively impact Xywav and Xyrem sales [469][472]. - The commercial success of Epidiolex/Epidyolex is uncertain, with potential competition from generic products and non-FDA approved CBD preparations [475]. Acquisitions and Strategic Moves - Chimerix Acquisition completed for $944.2 million, adding Modeyso to the oncology portfolio, which received FDA accelerated approval in August 2025 for treating H3 K27M mutation glioma [449]. - The company received FDA approval for Modeyso in August 2025 for treating diffuse midline glioma with H3 K27M mutation, following the acquisition of Chimerix [470]. - The company has entered into agreements with major PBMs in the U.S. to support the commercialization of Xywav [444]. - The New Repurchase Program authorized by the board allows for the repurchase of ordinary shares up to $500.0 million, replacing the previous program of $1.5 billion [512]. - In 2024, the company repurchased 2.8 million ordinary shares for a total of $311.4 million, with an average purchase price of $110.06 per share [512]. Cash Flow and Debt Management - Net cash provided by operating activities decreased by $40.1 million in 2025 to $1,355.8 million, primarily due to $323.5 million in litigation settlement expenses [515]. - Net cash used in investing activities increased by $1.0 billion in 2025 compared to 2024, driven by significant acquisitions and investments [517]. - The company reported a net cash outflow of $873.4 million from financing activities in 2025, a decrease of $893.9 million compared to 2024 [514]. - The Chimerix Acquisition resulted in an outflow of $858.1 million in 2025, contributing to the increase in investing activities [518]. - As of December 31, 2025, the company had cash, cash equivalents, and investments of $2.4 billion, with a long-term debt principal balance of $5.4 billion [507]. - The interest rate on the Tranche B-2 Dollar Term Loans was 5.97% as of December 31, 2025, with an effective interest rate of 8.32% [523]. - The company issued $1.0 billion principal amount of 2030 Notes in September 2024, with an interest rate of 3.125% per year [532]. - The Amended Revolving Credit Facility was increased from $500.0 million to $885.0 million in November 2024, extending the maturity date [524]. Tax and Valuation - The income tax benefit was $272.4 million in 2025, primarily due to the reversal of a valuation allowance against certain deferred tax assets [506]. - The company maintains a valuation allowance against certain deferred tax assets where realizability is not certain, evaluating the likelihood of realization periodically [570]. - The company did not recognize an impairment charge related to intangible assets in 2025, 2024, or 2023, indicating stable asset valuations [566]. - As of December 31, 2025, the company had $1.8 billion of goodwill resulting from acquisitions accounted for as business combinations, with no impairment recognized during 2025, 2024, or 2023 [559][566]. - The company reported $4.4 billion of finite-lived intangible assets as of December 31, 2025, with $3.2 billion related to the Epidiolex intangible asset and $0.9 billion related to the Vyxeos intangible asset [565]. Foreign Exchange and Risk Management - The company has significant operations in Europe and the U.S., exposing it to foreign currency exchange risk as financial statements of foreign subsidiaries are translated to U.S. dollars [578]. - A hypothetical 10% strengthening or weakening in exchange rates for sterling and euro would impact net income by $63.7 million and $6.9 million, respectively [579]. - As of December 31, 2025, the company held foreign exchange forward contracts with notional amounts totaling $575.9 million [580]. - The net asset fair value of outstanding foreign exchange forward contracts was $2.5 million as of December 31, 2025 [580]. - A hypothetical 10% adverse fluctuation in exchange rates would decrease the fair value of foreign exchange forward contracts by $21.1 million [580]. - The company has entered into foreign exchange forward contracts to manage currency risk, primarily related to sterling and euro denominated net monetary liabilities [580].